reviewed april 2026|next review october 2026|88 physicians psi has verified|1038 published studies
Thymosin Beta-4
Thymosin Beta-4 is a 43-amino-acid naturally occurring (the body's own) protein that is the primary intracellular actin-sequestering molecule in mammalian cells, with over 1,000 published studies documenting roles in wound healing, cardiac repair, and tissue regeneration.
Evidence landscape: 1038 published studies
1,038 published items. 13 human studies and 165 animal studies. One of the deepest evidence bases for any tissue repair peptide.
- 13 Human
- 165 Animal
- 22 Reviews
- 838 Other research
Over 1,000 published studies spanning wound healing, cardiac repair, and tissue regeneration.
RGN-259 corneal Phase II/III trial is the only controlled human data. Cardiac Nature papers (Bock-Marquette 2004, Smart 2007) are the most compelling animal evidence.
Not FDA-approved for any indication. RGN-259 ophthalmic formulation is in clinical development.
PSI Assessment
The research on Thymosin Beta-4 spans over 1,000 published studies documenting its role in wound healing, cardiac repair, and tissue regeneration - yet the only human clinical trials involve an eye drop formulation for corneal healing. That gap between the depth of basic science and the breadth of clinical application defines this compound. The wound healing biology is well-established, the cardiac repair data in animals is distinctive, but systemic human trial data remains sparse. Here is what the evidence supports and where the translation stalls.
Over 1,000 published studies. Nature-published cardiac repair data. The only controlled human data is from an eye drop formulation.
The mechanism centers on actin sequestration. Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin, regulating cytoskeletal dynamics in every nucleated mammalian cell. This actin regulation drives cell migration to injury sites, which is the mechanistic basis for wound healing effects across tissue types. The cardiac data is mechanistically distinct: Bock-Marquette et al. (2004, Nature) demonstrated Akt-mediated cardioprotection, and Smart et al. (2007, Nature) showed epicardial progenitor cell activation after myocardial infarction. TB-500 is a synthetic fragment corresponding to the active region.
What the evidence supports
Thymosin Beta-4 is the primary actin-sequestering protein in mammalian cells with over 1,000 published studies. Corneal wound healing is validated in Phase II/III clinical trials (RGN-259 ophthalmic formulation). Cardioprotection via Akt activation is demonstrated in two independent landmark studies published in Nature (Bock-Marquette 2004, Smart 2007). Dermal wound healing acceleration is consistently shown across animal models.
What is not yet established
Whether systemic administration produces meaningful tissue repair in humans. No human cardiac repair trial has been conducted despite the compelling animal data. Whether the injectable form used in functional medicine produces effects comparable to the controlled ophthalmic formulation. Whether Thymosin Beta-4 offers advantages over the TB-500 fragment for systemic applications.
Research Evidence
The findings below cover the corneal healing clinical program, the cardiac repair animal data, and the relationship between Thymosin Beta-4 and TB-500.
Evidence by condition
Evidence dimensions across Thymosin Beta-4's investigated applications. Corneal healing has the deepest clinical evidence. Cardiac repair has landmark animal data without human trials.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Corneal Healing | ||||
| Cardiac Repair | ||||
| Dermal Wound Healing | ||||
| Neuroprotection | ||||
| Hair Growth |
RGN-259 corneal Phase II/III clinical trials demonstrated accelerated corneal wound healing with the thymosin beta-4 ophthalmic formulation. This is the only controlled human clinical evidence.
The corneal healing application is the most clinically advanced and is the basis for the Human Trials rating.
Two independent landmark studies published in Nature demonstrated cardiac repair mechanisms: Bock-Marquette et al. (2004) showed Akt-mediated cardioprotection, and Smart et al. (2007) showed epicardial progenitor cell activation after myocardial infarction.
Publication in Nature by two independent groups provides strong academic credibility. No human cardiac repair trial has followed.
TB-500 is a synthetic fragment of Thymosin Beta-4 corresponding to the active region. The clinical trial data (RGN-259) uses the full protein, not the TB-500 fragment.
This distinction matters because most community discussion conflates the two, and whether they produce equivalent therapeutic effects is not established.
13 Human|165 Animal|22 Reviews
View all 1038 indexed studiesHow Thymosin Beta-4 Works
Thymosin Beta-4 is a 43-amino-acid protein encoded by the TMSB4X gene. It is the most abundant actin-sequestering molecule in mammalian cells, found in nearly every cell except red blood cells.
Thymosin Beta-4 controls how cells move by managing a structural protein called actin, the scaffolding that gives cells their shape. When tissue is damaged, cells need to migrate to the injury site and rebuild. Thymosin Beta-4 helps coordinate that process by controlling the supply of building materials (actin monomers) available for cells to use during repair. It also sends survival signals to heart cells during injury.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Thymosin Beta-4 binds G-actin monomers in a 1:1 complex, sequestering them from polymerization into F-actin filaments. This regulation of the actin pool is central to cell migration, proliferation, and differentiation during tissue repair. Beyond actin regulation, thymosin beta-4 activates the Akt (protein kinase B) survival signaling pathway in cardiomyocytes, promoting cell survival during ischemic injury. It also stimulates epicardial progenitor cells to differentiate into new coronary vessels and cardiomyocytes in developing and injured hearts.
What is Thymosin Beta-4 being studied for?
Researchers are studying Thymosin Beta-4 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymosin Beta-4 overall. This means a compound can have human studies for one condition but only animal data for another.
Corneal Healing
·Human TrialsThe RGN-259 ophthalmic formulation has completed Phase II/III clinical trials for corneal wound healing, demonstrating accelerated corneal re-epithelialization.
Limitations: FDA approval has not been granted. The ophthalmic formulation is specific to corneal surface healing and does not establish efficacy for other wound types or systemic applications.
Cardiac Repair
·Animal StudiesMultiple independent animal studies show thymosin beta-4 protects heart cells during injury and activates cardiac progenitor cells for repair. Two Nature publications provide the strongest evidence.
Limitations: All cardiac data is from animal models. No human cardiac repair trial has been conducted. The translation from rodent cardiac repair to human myocardial infarction recovery is historically unreliable.
Dermal Wound Healing
·Animal StudiesAnimal studies consistently show accelerated wound closure through enhanced cell migration and angiogenesis (new blood vessel formation).
Limitations: Human dermal wound healing data is limited to case reports and small uncontrolled studies. No randomized controlled trials have been published.
Neuroprotection
·PreclinicalEarly animal studies suggest neuroprotective properties and promotion of neural repair, but the evidence is preliminary.
Limitations: Very limited data from animal studies. No dedicated neuroprotection trials. Neuroprotective claims are extrapolations from general tissue repair mechanisms.
Hair Growth
·PreclinicalAnimal studies suggest thymosin beta-4 may stimulate hair follicle stem cells and promote hair growth.
Limitations: Very early data from animal studies. Human hair growth evidence has not been published.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication. RGN-259 ophthalmic formulation is in clinical development (RegeneRx Biopharmaceuticals).
Availability: Not on FDA lists that restrict or permit pharmacy preparation as a distinct compound from TB-500. Available through research channels.
Safety context: Thymosin Beta-4 is a naturally occurring (the body's own) protein found in nearly every nucleated cell. The RGN-259 ophthalmic formulation was well-tolerated in Phase II/III trials.
The RGN-259 ophthalmic formulation has been well-tolerated in clinical trials with no serious drug-related adverse events reported. Systemic safety data from controlled human trials is limited. Not FDA-approved for any indication.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Thymosin Beta-4 discussion.
Comparison and Related Research
Thymosin Beta-4 is most often compared with TB-500 (its synthetic fragment) and BPC-157 (a different tissue repair mechanism).
Head-to-head comparisons
Full research comparisons covering Thymosin Beta-4 and another peptide side by side.
Thymosin Beta-4 vs TB-500
TB-500 is a fragment of Thymosin Beta-4. Most research uses the full protein. What the difference means for evidence and clinical use.
View full comparisonThymosin Beta-4 vs Thymosin Alpha-1
Same organ of origin, completely different functions. TA1 modulates immune response. TB4 promotes tissue repair. Evidence-graded comparison.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.This landmark study demonstrated that thymosin beta-4 activates integrin-linked kinase (ILK) and the downstream Akt survival pathway in cardiomyocytes. In a mouse coronary ligation model, systemic administration of thymosin beta-4 reduced infarct size and improved cardiac function. The findings established a molecular mechanism linking thymosin beta-4 to cardiac cell survival and tissue repair.Bock-Marquette I et al., 2004 in Nature. View on PubMed
- 2.This study showed that thymosin beta-4 reactivates dormant epicardial progenitor cells in adult mouse hearts, prompting them to migrate into damaged myocardium and form new blood vessels. The research provided the first evidence that an exogenous peptide could reprogram adult epicardial cells to participate in cardiac repair, opening a potential path toward regenerative medicine for heart disease.Smart N et al., 2007 in Nature. View on PubMed
- 3.A Phase II randomized, placebo-controlled clinical trial evaluated the thymosin beta-4-based ophthalmic solution RGN-259 in patients with dry eye disease. Using a controlled adverse environment chamber to standardize symptom provocation, the trial showed improvements in several dry eye signs, including corneal staining. The results supported moving into larger efficacy trials for this indication.Sosne G et al., 2015 in Clin Ophthalmol. View on PubMed
- 4.An early study demonstrating that thymosin beta-4 accelerates dermal wound healing in a rat full-thickness punch biopsy model. Treated wounds showed increased collagen deposition, angiogenesis, and keratinocyte migration compared to controls. This was among the first published evidence that thymosin beta-4 promotes tissue repair in a living organism.Malinda KM et al., 1999 in J Invest Dermatol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.